Review Quality Rating: 8 (strong)
Citation: Guirguis-Blake J, Evans C, Senger C, O'Connor E, & Whitlock E. (2016). Aspirin for the primary prevention of cardiovascular events: A systematic evidence review for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 164(12), 804-813.Article full-text (free) PubMed LinkOut
In Canada and a number of other countries, ASPIRIN® is a valid registered trade mark of Bayer AG for products containing acetylsalicylic acid or ASA. In such countries it is not permissible to use "aspirin" as the generic name of the drug. Any reference to "aspirin" in any documents accessed through this site that originate outside Canada should therefore be read with this understanding in mind.
BACKGROUND: Cardiovascular disease (CVD) is the leading cause of death in the United States.
PURPOSE: To update a systematic review about the benefits of aspirin for the primary prevention of cardiovascular events in adults aged 40 years or older and to evaluate effect modification in subpopulations.
DATA SOURCES: MEDLINE, PubMed, Cochrane Central Register of Controlled Trials (January 2008 to January 2015), and Cochrane Database of Systematic Reviews.
STUDY SELECTION: Two investigators independently reviewed 3396 abstracts and 65 articles according to prespecified criteria. All included trials evaluated aspirin for the primary prevention of cardiovascular events.
DATA EXTRACTION: Two investigators assessed study quality; data were abstracted by 1 reviewer and checked by a second.
DATA SYNTHESIS: Two good-quality and 9 fair-quality randomized, controlled trials were identified. In analyses of all doses, aspirin reduced the risk for nonfatal myocardial infarction (MI) (relative risk [RR], 0.78 [95% CI, 0.71 to 0.87]) but not nonfatal stroke; aspirin showed little or no benefit for all-cause or cardiovascular mortality. Benefits began within the first 5 years. Older adults achieved greater relative MI reduction, but no other effect modifications were found in analyzed subpopulations. In trials with aspirin doses of 100 mg or less per day, the reduction in nonfatal MI benefit persisted (absolute risk reduction, 0.15 to 1.43 events per 1000 person-years) and a 14% reduction in nonfatal stroke benefit was noted, but no benefit was found for all-cause mortality (RR, 0.95 [CI, 0.89 to 1.01]) or cardiovascular mortality (RR, 0.97 [CI, 0.85 to 1.10]).
LIMITATION: Evidence for aspirin in primary prevention is heterogeneous and limited by rare events and few credible subgroup analyses.
CONCLUSION: The beneficial effect of aspirin for the primary prevention of CVD is modest and occurs at doses of 100 mg or less per day. Older adults seem to achieve a greater relative MI benefit.
PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.
Adults (20-59 years), Adult's Health (men's health, women's health), Behaviour Modification (e.g., provision of item/tool, incentives, goal setting), Cardiovascular Disease, Community, Home, Meta-analysis, Senior Health, Seniors (60+ years)